source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
THELINCOLNIANONLINE | 2020-02-21 20:21:00 | https://www.thelincolnianonline.com/2020/02/21/jennison-associates-llc-has-61-09-million-holdings-in-ameris-bancorp-nasdaqabcb.html | Jennison Associates LLC boosted its position in Ameris Bancorp (NASDAQ:ABCB) by 48.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,436,059 shares of the bank’s stock after buying an additional 469,177 shares during the quarter. Jennison... | Jennison Associates LLC Has $61.09 Million Holdings in Ameris Bancorp (NASDAQ:ABCB) | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-02-21 16:08:42 | https://www.thelincolnianonline.com/2020/02/21/ameris-bancorp-nasdaqabcb-position-boosted-by-rhumbline-advisers.html | Rhumbline Advisers grew its holdings in shares of Ameris Bancorp (NASDAQ:ABCB) by 7.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 225,419 shares of the bank’s stock after purchasing an additional 15,962 shares during the period. Rhumbline Advisers’ holdings in Ameris Bancorp were worth $9,589,000 a... | Ameris Bancorp (NASDAQ:ABCB) Position Boosted by Rhumbline Advisers | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
YAHOO | 2020-02-21 14:44:02 | https://finance.yahoo.com/news/does-market-timing-actually-february-144402949.html | Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art? | When Does Market Timing Actually Work? - February 21, 2020 | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
ZACKS | 2020-02-21 14:44:00 | https://www.zacks.com/stock/news/777089/when-does-market-timing-actually-work-february-21-2020 | Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art? | When Does Market Timing Actually Work? - February 21, 2020 | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-02-21 14:10:45 | https://www.thelincolnianonline.com/2020/02/21/sg-americas-securities-llc-trims-position-in-ameris-bancorp-nasdaqabcb.html | SG Americas Securities LLC lowered its position in shares of Ameris Bancorp (NASDAQ:ABCB) by 51.1% during the fourth quarter, Holdings Channel reports. The fund owned 4,157 shares of the bank’s stock after selling 4,349 shares during the quarter. SG Americas Securities LLC’s holdings in Ameris Bancorp were worth $177,0... | SG Americas Securities LLC Trims Position in Ameris Bancorp (NASDAQ:ABCB) | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THEFLY | 2020-02-20 14:17:24 | https://thefly.com/permalinks/entry.php/id3036931/SONA;ABCB-Southern-National-Bancorp-names-Dennis-Zember-Jr-as-CEO | Southern National Bancorp names Dennis Zember Jr. as CEO SONA ABCB | Southern National Bancorp names Dennis Zember Jr. as CEO SONA;ABCB | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
YAHOO | 2020-02-20 14:15:00 | https://finance.yahoo.com/news/appointment-dennis-j-zember-jr-141500146.html | Southern National Bancorp of Virginia, Inc. (NASDAQ: SONA) ("Southern National" or the "Company") announced today that Dennis J. Zember Jr. has been appointed President and Chief Executive Officer of Southern National and its wholly-owned subsidiary, Sonabank, as well as a member | Appointment of Dennis J. Zember Jr. as President and Chief Executive Officer of Southern National Bancorp of Virginia, Inc. | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-02-20 11:30:42 | https://www.thelincolnianonline.com/2020/02/20/ameris-bancorp-nasdaqabcb-stock-rating-upgraded-by-valuengine.html | Ameris Bancorp (NASDAQ:ABCB) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Tuesday, ValuEngine reports. Other equities analysts have also recently issued reports about the stock. BidaskClub cut shares of Ameris Bancorp from a “sell” rating to a “strong sel... | Ameris Bancorp (NASDAQ:ABCB) Stock Rating Upgraded by ValuEngine | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-02-15 13:30:52 | https://www.thelincolnianonline.com/2020/02/15/first-interstate-bank-trims-stock-holdings-in-ameris-bancorp-nasdaqabcb.html | First Interstate Bank lowered its holdings in Ameris Bancorp (NASDAQ:ABCB) by 93.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 577 shares of the bank’s stock after selling 8,364 shares during the period. First Interstate Bank’s holdings in Ameris Bancorp were worth ... | First Interstate Bank Trims Stock Holdings in Ameris Bancorp (NASDAQ:ABCB) | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-02-11 16:51:02 | https://www.thelincolnianonline.com/2020/02/11/oak-ridge-investments-llc-cuts-stock-position-in-ameris-bancorp-nasdaqabcb.html | Oak Ridge Investments LLC decreased its stake in shares of Ameris Bancorp (NASDAQ:ABCB) by 9.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 237,483 shares of the bank’s stock after selling 23,969 shares during the quarter. Oak Ridge Inv... | Oak Ridge Investments LLC Cuts Stock Position in Ameris Bancorp (NASDAQ:ABCB) | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
SEEKINGALPHA | 2020-02-03 14:08:26 | https://seekingalpha.com/news/3537260-banks-may-gain-coronavirus-affects-u-s-suntrust-says | News is free at Seeking Alpha.This post is a Notable Call. Notable Calls are a Premium feature.To access this and other Notable Calls, try a free trial to Seeking Alpha Premium. | These banks may gain if coronavirus affects U.S., SunTrust says | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-02-01 06:01:01 | https://www.thelincolnianonline.com/2020/02/01/traders-purchase-large-volume-of-ameris-bancorp-call-options-nasdaqabcb.html | Ameris Bancorp (NASDAQ:ABCB) was the recipient of some unusual options trading on Thursday. Investors bought 614 call options on the stock. This represents an increase of approximately 765% compared to the typical daily volume of 71 call options. ABCB has been the topic of several recent research reports. Zacks Investm... | Traders Purchase Large Volume of Ameris Bancorp Call Options (NASDAQ:ABCB) | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-01-31 14:21:02 | https://finance.yahoo.com/news/timing-market-possible-january-31-142102699.html?.tsrc=rss | Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets? | Timing the Market, Is it Possible? - January 31, 2020 | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
ZACKS | 2020-01-31 14:21:00 | https://www.zacks.com/stock/news/742577/timing-the-market-is-it-possible-january-31-2020 | Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets? | Timing the Market, Is it Possible? - January 31, 2020 | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-01-30 07:56:41 | https://www.thelincolnianonline.com/2020/01/30/equities-analysts-issue-forecasts-for-ameris-bancorps-fy2020-earnings-nasdaqabcb.html | Ameris Bancorp (NASDAQ:ABCB) – Equities researchers at Piper Sandler dropped their FY2020 EPS estimates for shares of Ameris Bancorp in a note issued to investors on Sunday, January 26th. Piper Sandler analyst C. Whitman now forecasts that the bank will earn $4.10 per share for the year, down from their prior forecast ... | Equities Analysts Issue Forecasts for Ameris Bancorp's FY2020 Earnings (NASDAQ:ABCB) | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-01-30 07:06:41 | https://www.thelincolnianonline.com/2020/01/30/ameris-bancorp-expected-to-post-q1-2020-earnings-of-0-94-per-share-nasdaqabcb.html | Ameris Bancorp (NASDAQ:ABCB) – Equities research analysts at Piper Sandler issued their Q1 2020 EPS estimates for Ameris Bancorp in a research note issued on Sunday, January 26th. Piper Sandler analyst C. Whitman anticipates that the bank will post earnings of $0.94 per share for the quarter. Piper Sandler also issued ... | Ameris Bancorp Expected to Post Q1 2020 Earnings of $0.94 Per Share (NASDAQ:ABCB) | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
FOOL | 2020-01-29 15:36:00 | https://www.fool.com/investing/2020/01/29/2-banks-with-impressive-fourth-quarter-earnings-an.aspx?source=iedfolrf0000001 | Here are our winners of bank earnings season and much more. | 2 Banks With Impressive Fourth-Quarter Earnings and What to Do When the Market Sells Off | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-01-29 10:04:44 | https://www.thelincolnianonline.com/2020/01/29/ameris-bancorp-nasdaqabcb-upgraded-to-sell-at-valuengine.html | ValuEngine upgraded shares of Ameris Bancorp (NASDAQ:ABCB) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday morning, ValuEngine reports. Several other equities research analysts have also recently commented on ABCB. Stephens started coverage on Ameris Bancorp in a report on F... | Ameris Bancorp (NASDAQ:ABCB) Upgraded to "Sell" at ValuEngine | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-01-28 17:48:54 | https://finance.yahoo.com/news/edited-transcript-abcb-earnings-conference-154721638.html?.tsrc=rss | Q4 2019 Ameris Bancorp Earnings Call | Edited Transcript of ABCB earnings conference call or presentation 24-Jan-20 2:30pm GMT | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
YAHOO | 2020-01-27 15:47:21 | https://finance.yahoo.com/news/edited-transcript-abcb-earnings-conference-154721638.html | Q4 2019 Ameris Bancorp Earnings Call | Edited Transcript of ABCB earnings conference call or presentation 24-Jan-20 2:30pm GMT | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
SEEKINGALPHA | 2020-01-24 19:48:08 | https://seekingalpha.com/article/4318966-ameris-bancorp-abcb-ceo-palmer-proctor-on-q4-2019-results-earnings-call-transcript | Ameris Bancorp (NASDAQ:ABCB) Q4 2019 Results Conference Call January 24, 2020 09:30 AM ET Company Participants Nicole Stokes - Chief Financial Officer Palmer Pr | Ameris Bancorp (ABCB) CEO Palmer Proctor on Q4 2019 Results - Earnings Call Transcript | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
FOOL | 2020-01-24 19:01:01 | https://www.fool.com/earnings/call-transcripts/2020/01/24/ameris-bancorp-abcb-q4-2019-earnings-call-transcri.aspx?source=iedfolrf0000001 | ABCB earnings call for the period ending December 31, 2019. | Ameris Bancorp (ABCB) Q4 2019 Earnings Call Transcript | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THEFLY | 2020-01-24 12:59:09 | https://thefly.com/permalinks/entry.php/id3022494/ABCB-Ameris-Bancorp-says-growth-prospects-for-TBV-capital-levels-are-very-attractive | Ameris Bancorp says growth prospects for TBV, capital levels are very attractive ABCB | Ameris Bancorp says growth prospects for TBV, capital levels are very attractive ABCB | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo | 2020-01-23 23:25:11 | https://finance.yahoo.com/news/ameris-bancorp-abcb-meets-q4-232511359.html?.tsrc=rss | Ameris Bancorp (ABCB) delivered earnings and revenue surprises of 0.00% and -1.58%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock? | Ameris Bancorp (ABCB) Meets Q4 Earnings Estimates | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
ZACKS | 2020-01-23 23:25:03 | https://www.zacks.com/stock/news/731038/ameris-bancorp-abcb-meets-q4-earnings-estimates | Ameris Bancorp (ABCB) delivered earnings and revenue surprises of 0.00% and -1.58%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock? | Ameris Bancorp (ABCB) Meets Q4 Earnings Estimates | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
HOUSTONCHRONICLE | 2020-01-23 22:35:23 | https://www.houstonchronicle.com/business/article/Ameris-Bancorp-4Q-Earnings-Snapshot-14999545.php | MOULTRIE, Ga. (AP) _ Ameris Bancorp (ABCB) on Thursday reported fourth-quarter earnings of $61.2 million. The Moultrie, Georgia-based bank said it had earnings of 88 cents per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 96 cents per share. The results met Wal... | Ameris Bancorp: 4Q Earnings Snapshot | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
YAHOO | 2020-01-23 22:34:13 | https://finance.yahoo.com/news/ameris-bancorp-4q-earnings-snapshot-223413521.html | MOULTRIE, Ga. (AP) _ Ameris Bancorp (ABCB) on Thursday reported fourth-quarter earnings of $61.2 million.
The Moultrie, Georgia-based bank said it had earnings of 88 cents per share. Earnings, adjusted for non-recurring costs and costs related to mer | Ameris Bancorp: 4Q Earnings Snapshot | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PR Newswire | 2020-01-23 22:13:00 | https://www.prnewswire.com:443/news-releases/ameris-bancorp-announces-fourth-quarter-and-full-year-2019-financial-results-300992533.html | ATLANTA, Jan. 23, 2020 /PRNewswire/ -- Ameris Bancorp (Nasdaq: ABCB) (the "Company") today reported net income of $61.2 million, or $0.88 per diluted share, for the quarter ended December 31, 2019, compared with $43.5 million, or $0.91 per diluted share, for the quarter ended December 31,… | Ameris Bancorp Announces Fourth Quarter And Full Year 2019 Financial Results | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-01-19 09:30:31 | https://www.thelincolnianonline.com/2020/01/19/piper-sandler-weighs-in-on-ameris-bancorps-fy2020-earnings-nasdaqabcb.html | Ameris Bancorp (NASDAQ:ABCB) – Research analysts at Piper Sandler issued their FY2020 earnings estimates for shares of Ameris Bancorp in a report issued on Tuesday, January 14th. Piper Sandler analyst C. Whitman anticipates that the bank will post earnings per share of $4.18 for the year. Other analysts have also recen... | Piper Sandler Weighs in on Ameris Bancorp's FY2020 Earnings (NASDAQ:ABCB) | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-01-17 07:40:49 | https://www.thelincolnianonline.com/2020/01/17/reviewing-ameris-bancorp-nasdaqabcb-oritani-financial-nasdaqorit.html | Oritani Financial (NASDAQ:ORIT) and Ameris Bancorp (NASDAQ:ABCB) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership. Analyst Recommendatio... | Reviewing Ameris Bancorp (NASDAQ:ABCB) & Oritani Financial (NASDAQ:ORIT) | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
THELINCOLNIANONLINE | 2020-01-17 06:44:41 | https://www.thelincolnianonline.com/2020/01/17/ameris-bancorp-nasdaqabcb-sees-large-increase-in-short-interest.html | Ameris Bancorp (NASDAQ:ABCB) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 2,230,000 shares, an increase of 7.2% from the December 15th total of 2,080,000 shares. Approximately 3.4% of the shares of the company are short sold. Based on an avera... | Ameris Bancorp (NASDAQ:ABCB) Sees Large Increase in Short Interest | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
ZACKS | 2020-01-16 17:30:51 | https://www.zacks.com/stock/news/721100/ameris-bancorp-abcb-reports-next-week-what-to-expect | Ameris Bancorp (ABCB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | Ameris Bancorp (ABCB) Reports Next Week: What to Expect | ABCB | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
OTC PR Wire | 2021-04-08 15:20:07 | https://otcprwire.com/abco-energy-announces-entry-into-solar-asset-operation-and-maintenance-business/ | Tucson, Arizona, April 8, 2021 – OTC PR WIRE -.ABCO Energy, Inc. (OTC Pink: ABCE), the Arizona provider of integrated energy solutions, is pleased to announce the addition of the solar asset management business to its portfolio of services and construction business. ABCO manages and repairs systems for its own custome... | ABCO ENERGY ANNOUNCES ENTRY INTO SOLAR ASSET OPERATION AND MAINTENANCE BUSINESS | ABCE | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Newsfile Corp | 2021-04-08 15:17:00 | https://www.newsfilecorp.com/release/79856/ABCO-Energy-Announces-Entry-into-Solar-Asset-Operation-and-Maintenance-Business | Tucson, Arizona--(Newsfile Corp. - April 8, 2021) - ABCO Energy, Inc. (OTC Pink: ABCE), the Arizona provider of integrated energy solutions, is pleased to announce the addition of the solar asset management business to its portfolio of services and construction business. ABCO manages and repairs systems for its own cus... | ABCO Energy Announces Entry into Solar Asset Operation and Maintenance Business | ABCE | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-07-08 20:43:12 | https://investorplace.com/2023/07/looking-for-biotech-ai-stocks-3-names-that-will-benefit-from-the-ai-boom/ | AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery. | Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2023-05-29 16:05:00 | https://www.businesswire.com/news/home/20230525005760/en/AbCellera-to-Present-at-the-Goldman-Sachs-44th-Annual-Global-Healthcare-Conference-on-June-13-2023/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023. | AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-05-14 14:57:59 | https://investorplace.com/2023/05/7-growth-stocks-that-could-double-your-money-in-2023/ | While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks. | 7 Growth Stocks That Could Double Your Money in 2023 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-05-06 00:42:48 | https://seekingalpha.com/article/4600801-abcellera-biologics-stock-tce-program-alone-could-be-worth-more-than-the-current-market-cap | AbCellera reported results from the first quarter on May 4th. To put it bluntly, the actual earnings print means next to nothing in this name at this stage. The company had a very busy and productive quarter under the surface, reporting progress on multiple fronts, specifically the TCE program (T-cell engager). | AbCellera Biologics: TCE Program Alone Could Be Worth More Than The Current Market Cap | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-05-04 21:30:23 | https://seekingalpha.com/article/4600250-abcellera-biologics-inc-abcl-q1-2023-earnings-call-transcript | AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldma... | AbCellera Biologics Inc. (ABCL) Q1 2023 Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-05-04 19:01:59 | https://www.zacks.com/stock/news/2090371/abcellera-biologics-inc-abcl-reports-q1-loss-tops-revenue-estimates | AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.54 per share a year ago. | AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-04-24 19:46:01 | https://investorplace.com/2023/04/7-stocks-under-10-that-analysts-love/ | Generally speaking, you get what you pay for, which on paper doesn't bode well for these bargain stocks under $10. Nevertheless, with thousands upon thousands of tradable securities available to public investors, at least a few will go unnoticed. | 7 Stocks Under $10 That Analysts Love | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-04-11 19:31:03 | https://investorplace.com/2023/04/7-best-stocks-under-10-to-buy-in-april/ | Although financial advisors often direct you to established, reliable enterprises, in some cases, you can find compelling ideas among the best stocks under $10. To be fair, such companies tend to be more volatile than your standard blue-chip fare. | 7 Best Stocks Under $10 to Buy in April | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2023-04-11 16:05:00 | https://www.businesswire.com/news/home/20230406005772/en/AbCellera-to-Present-at-the-2023-Bloom-Burton-Co.-Healthcare-Investor-Conference-on-April-25-2023/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 2023 Bloom Burton & Co. | AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-04-05 13:40:01 | https://investorplace.com/2023/04/7-thrilling-biotech-stocks-for-aggressive-investors-to-buy/ | While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — ... | 7 Thrilling Biotech Stocks for Aggressive Investors to Buy | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-04-01 05:17:00 | https://seekingalpha.com/article/4591682-confoundeds-complete-all-weather-portfolio-revealed | Most readers follow my work for the extensive writing I have done referencing my aggressive growth portfolio. However, the vast majority of my net worth is held in my all-weather portfolio. In this article, I would like to draw back the curtain on my main, all-weather portfolio, where roughly 80% of my assets reside. | Confounded's Complete All-Weather Portfolio Revealed | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-03-22 15:26:51 | https://investorplace.com/2023/03/7-stocks-to-bet-on-if-you-want-to-be-richer-than-elon-musk/ | If you aspire to one day topple entrepreneurial genius Elon Musk on the net wealth rankings through the equities market exclusively, you're obviously going to need to conduct heavy research on the stocks that can make you rich. However, you also want to be smart about this. | 7 Stocks to Bet On if You Want to Be Richer Than Elon Musk | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-02-21 19:47:05 | https://seekingalpha.com/article/4580403-abcellera-biologics-inc-abcl-q4-2022-earnings-call-transcript | AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fauth - Cr... | AbCellera Biologics Inc (ABCL) Q4 2022 Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-02-21 18:49:19 | https://www.zacks.com/stock/news/2057110/abcellera-biologics-inc-abcl-reports-q4-loss-misses-revenue-estimates | AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? | AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2023-02-02 14:19:39 | https://investorplace.com/2023/02/the-7-most-undervalued-biotech-stocks-to-buy-in-february-2023/ | You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science. | The 7 Most Undervalued Biotech Stocks to Buy in February 2023 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2023-02-01 16:05:00 | https://www.businesswire.com/news/home/20230130005739/en/AbCellera-to-Present-at-the-SVB-Securities-Global-Biopharma-Conference-on-February-15-2023/ | VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). | AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2023-01-24 10:33:02 | https://www.zacks.com/stock/news/2043183/is-the-options-market-predicting-a-spike-in-abcellera-abcl-stock | Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately. | Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock? | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-01-05 02:57:24 | https://seekingalpha.com/article/4567955-abcellera-biologics-my-updated-current-valuation-estimate | In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. In the last year, many of my inputs I previously used have changed, given the greater transparency of the company throughout 2022. Some for the better, some for the worse. | AbCellera Biologics: My Updated Current Valuation Estimate | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2023-01-04 11:04:24 | https://seekingalpha.com/article/4567804-10-potential-10x-return-stocks-for-the-next-10-years | While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific. | 10 Potential 10x Return Stocks For The Next 10 Years | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-11-09 01:45:16 | https://seekingalpha.com/article/4555204-abcellera-biologics-stock-q3-earnings-moving-up-value-stack | AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines. The company, in the days before the release, indicated that Regeneron has advanced its first GCPR target into preclinical development, further validating its platform. | AbCellera Biologics: Q3 Commentary - Moving Up The Value Stack | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-11-08 21:14:11 | https://seekingalpha.com/article/4555108-abcellera-biologics-inc-abcl-q3-2022-earnings-call-transcript | AbCellera Biologics Inc (NASDAQ:ABCL ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer and President Andrew Booth - Chief Financial Officer Conference Call Participants Do Kim - Piper Sand... | AbCellera Biologics Inc (ABCL) Q3 2022 Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-11-08 20:18:37 | https://www.zacks.com/stock/news/2015771/abcellera-biologics-inc-abcl-q3-earnings-miss-estimates | AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? | AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2022-11-04 16:05:00 | https://www.businesswire.com/news/home/20221104005586/en/AbCellera-to-Present-at-Upcoming-Investor-Conferences-in-November/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November | AbCellera to Present at Upcoming Investor Conferences in November | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-11-01 11:18:56 | https://www.zacks.com/stock/news/2011857/abcellera-biologics-inc-abcl-reports-next-week-wall-street-expects-earnings-growth | AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-08-14 00:42:32 | https://seekingalpha.com/article/4534101-abcellera-biologics-covid-antibody-continued-funding | AbCellera Biologics reported Q2 numbers that were not all that impressive; however, the news of the commercialization agreement its partner Lilly inked has driven shares to near YTD highs. The commercialization plan looks to provide AbCellera with continued non-dilutive funding to further build its now $1 billion cash ... | AbCellera Biologics: COVID Antibody Set To Provide Continued Funding | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2022-08-10 18:17:49 | https://pulse2.com/abcellera-reports-q2-2022-business-results/ | AbCellera (ABCL) recently announced its Q2 2022 business results. These are the details. | AbCellera Reports Q2 2022 Business Results | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-08-10 13:20:28 | https://www.fool.com/investing/2022/08/10/why-abcellera-biologics-rallied-as-much-as-24-on-w/ | The contract drug developer's stock is finally shaking off the froth of its initial public offering. | Why AbCellera Biologics Rallied as Much as 24% on Wednesday | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-08-10 00:10:04 | https://seekingalpha.com/article/4532341-abcellera-biologics-inc-abcl-ceo-dr-carl-hansen-on-q2-2022-results-earnings-call-transcript | AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and CEO Andrew Booth - CFO Conference Call Participants Tiago Fauth - Credit Suisse Puneet Souda - SVB Securities Stephen ... | AbCellera Biologics Inc. (ABCL) CEO Dr. Carl Hansen on Q2 2022 Results - Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-08-09 19:33:33 | https://www.zacks.com/stock/news/1966311/abcellera-biologics-inc-abcl-reports-q2-loss-misses-revenue-estimates | AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? | AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2022-07-12 16:05:00 | https://www.businesswire.com/news/home/20220712005059/en/AbCellera-to-Report-Second-Quarter-2022-Financial-Results-on-August-9-2022/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022 | AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-06-20 10:06:13 | https://www.zacks.com/stock/news/1941091/abcellera-biologics-inc-abcl-stock-jumps-9-3-will-it-continue-to-soar | AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. | AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar? | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-06-06 07:24:30 | https://seekingalpha.com/article/4516613-abcellera-biologics-fully-funded-new-opportunities-massive-insider-buying | AbCellera stock has continued to struggle of late given the absolutely terrible sentiment in the biotech market, however the company's actual business is thriving under the surface. In the Q1 earnings call, the company highlighted both the internally developed T-Cell engager platform, along with the Empirico deal which... | AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-11 12:54:31 | https://www.fool.com/investing/2022/05/11/why-abcellera-biologics-is-10-lower-today/ | The company has a plan for life after COVID-19, though it pales in comparison. | Why AbCellera Biologics Is 10% Lower Today | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-05-10 21:55:10 | https://seekingalpha.com/article/4509871-abcellera-biologics-inc-abcl-ceo-dr-carl-hansen-on-q1-2022-results-earnings-call-transcript | AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2022 Results Conference Call May 10, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fauth - Credit Suisse P... | AbCellera Biologics Inc. (ABCL) CEO Dr. Carl Hansen on Q1 2022 Results - Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-05-10 18:49:08 | https://www.zacks.com/stock/news/1922253/abcellera-biologics-inc-abcl-beats-q1-earnings-and-revenue-estimates | AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? | AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-04-26 07:17:21 | https://investorplace.com/2022/04/3-biotech-stocks-under-10-to-add-to-your-buy-list/ | These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on InvestorPlace. | 3 Biotech Stocks Under $10 to Add to Your Buy List | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-04-22 01:50:00 | https://seekingalpha.com/article/4502877-abcellera-biologics-stock-potentially-bottoming-out | AbCellera, the stock, has had a woeful two plus years as a public company; however, AbCellera the business is performing brilliantly. The company recently announced an internally developed T-Cell engager program that it is looking to partner, likely at attractive terms for AbCellera, giving the company another avenue t... | AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2022-04-12 16:05:00 | https://www.businesswire.com/news/home/20220411005730/en/AbCellera-to-Report-First-Quarter-2022-Financial-Results-on-May-10-2022/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022 | AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-02-24 23:15:05 | https://seekingalpha.com/article/4490348-abcellera-biologics-inc-abcl-ceo-carl-hansen-on-q4-2021-earnings-call-transcript | Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q4 2021 Earnings Call Transcript | Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q4 2021 Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2022-02-11 16:05:00 | https://www.businesswire.com/news/home/20220211005577/en/AbCellera-to-Present-Virtually-at-the-11th-Annual-SVB-Leerink-Global-Healthcare-Conference-on-February-17-2022/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022 | AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-02-11 08:45:28 | https://seekingalpha.com/article/4486286-abcellera-biologics-bebtelovimab-supply-deal-potential | AbCellera announced on Thursday Feb 10th a supply deal with the US government and Lilly for Bebtelovimab, the AbCellera developed pan COVID variant antibody treatment. | AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-05 00:17:56 | https://seekingalpha.com/article/4473437-abcellera-biologics-potentially-worth-over-41-currently-without-covid-revenues | AbCellera has been pummeled in the market this year, dropping like a stone to the current price of just over $14 a share. I believe this is a huge mistake. AbCellera currently has 131 programs with royalty agreements under contract and that number continues to grow fast. | AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-09 21:09:09 | https://seekingalpha.com/article/4467670-abcellera-biologics-inc-abcl-ceo-carl-hansen-on-q3-2021-results-earnings-call-transcript | Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q3 2021 Results - Earnings Call Transcript | Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q3 2021 Results - Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-11-04 10:57:48 | https://www.fool.com/investing/2021/11/04/why-abcellera-biologics-stock-sank-216-in-october/ | The biotech is now down roughly 56% across 2021's trading. | Why AbCellera Biologics Stock Sank 21.6% in October | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-18 03:45:18 | https://seekingalpha.com/article/4460317-abcellera-biologics-stock-covid-premium-gone-thanks-to-merck-time-to-buy | AbCellera shares have been rocked by news of Merck's "COVID pill" treatment, sending shares down 25% from recent highs. In September, AbCellera's current antibody therapy was put back into use after an FDA pause, giving the company back a key revenue source | AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-07 07:59:41 | https://www.fool.com/investing/2021/10/07/why-abcellera-biologics-stock-jumped-194-in-septem/ | Despite last month's gains, the biotech stock is now down roughly 61% year to date. | Why AbCellera Biologics Stock Jumped 19.4% Last Month | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-23 15:18:16 | https://www.zacks.com/stock/news/1800298/abcellera-abcl-everest-to-co-develop-new-antibody-therapies | AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications. | AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-09-22 18:00:00 | https://www.prnewswire.com/news-releases/abcellera-and-everest-medicines-announce-multi-target-collaboration-to-advance-new-antibody-therapies-301382949.html | VANCOUVER, British Columbia and SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Evere... | AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-09-21 13:55:00 | https://www.businesswire.com/news/home/20210921006004/en/Lilly-to-Supply-the-EU-and-EEA-with-up-to-220000-Doses-of-AbCellera-Discovered-Bamlanivimab-Together-with-Etesevimab-for-the-Treatment-of-Confirmed-COVID-19/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 | Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-09-17 08:51:03 | https://pulse2.com/abcellera-biologics-nasdaq-abcl-stock-why-it-increased-today/ | The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) increased by over 16% pre-market. This is why it happened. | ABCL Stock: Why It Increased Today | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-09-17 06:34:42 | https://www.benzinga.com/general/biotech/21/09/22983998/abcellera-stock-is-moving-higher-after-expanded-use-nod-for-lilly-partnered-covid-19-antibody | The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SARS-CoV-2 infection. Bamlanivimab emerged from the collaboration between Eli Lilly And Co (NYSE: LLY) and AbCellera Bio... | AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-09-16 16:15:00 | https://www.businesswire.com/news/home/20210916005867/en/Emergency-Use-Authorization-of-AbCellera-Discovered-Bamlanivimab-Administered-with-Etesevimab-Expanded-by-the-FDA-to-Include-Post-Exposure-Prophylaxis-for-the-Prevention-of-COVID-19/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--EUA of Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19 | Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-15 18:33:03 | https://www.fool.com/investing/2021/09/15/why-abcellera-biologics-jumped-7-on-wednesday/ | The company's drug-development technology is starting to attract attention. | Why AbCellera Biologics Stock Jumped 7% on Wednesday | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-09-15 09:31:03 | https://www.benzinga.com/general/biotech/21/09/22951378/abcellera-shares-are-moving-higher-on-licensing-pact-with-moderna | AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for mRNA medicines. The collaboration will leverage AbCellera's AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies ag... | AbCellera Shares Are Moving Higher On Licensing Pact With Moderna | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-09-10 16:17:00 | https://www.businesswire.com/news/home/20210910005540/en/AbCellera-to-Present-Virtually-at-the-BofA-Securities-%E2%80%93-Tech-Solutions-for-Drug-Discovery-Conference/ | VANCOUVER--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference | AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-04 11:12:39 | https://www.fool.com/investing/2021/09/04/heres-why-abcellera-biologics-stock-gained-106-las/ | Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading. | Here's Why AbCellera Biologics Stock Gained 10.6% Last Month | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-20 10:13:15 | https://seekingalpha.com/article/4450898-abcellera-biologics-i-was-wrong | AbCellera reported Q2 results on 08/12/21 which were well received by the market, sending shares up 15%. A remark by the CEO in the conference call, however, has me quite concerned. The company since IPO has indicated that royalties negotiated are between single digits and low double digits, allowing the impression to ... | AbCellera Biologics: I Was Wrong | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-13 12:52:36 | https://www.fool.com/investing/2021/08/13/why-abcellera-biologics-is-up-more-than-17-on-frid/ | The biopharma company's second quarter was better than expected. The future looks pretty bright, too. | Why AbCellera Biologics Stock Was Up More Than 17% on Friday | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-12 21:56:03 | https://seekingalpha.com/article/4448938-abcellera-biologics-inc-abcl-ceo-carl-hansen-on-q2-2021-results-earnings-call-transcript | AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q2 2021 Results - Earnings Call Transcript | AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q2 2021 Results - Earnings Call Transcript | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-08-12 16:05:00 | https://www.businesswire.com/news/home/20210812005750/en/AbCellera-Reports-Q2-2021-Business-Results/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q2 2021 Business Results | AbCellera Reports Q2 2021 Business Results | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-06 04:54:00 | https://seekingalpha.com/article/4445853-abcellera-biologics-a-buy-at-current-prices | AbCellera Biologics: A Buy At Current Prices | AbCellera Biologics: A Buy At Current Prices | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-08-03 06:00:00 | https://www.businesswire.com/news/home/20210803005352/en/Tachyon-and-AbCellera-Collaborate-to-Develop-Novel-Antibody-Therapeutic-Targeting-TGF-%CE%B2-Superfamily-Member-for-the-Treatment-of-Cancer/ | HOUSTON & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer | Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-07-22 16:05:00 | https://www.businesswire.com/news/home/20210722005812/en/AbCellera-to-Report-Second-Quarter-2021-Financial-Results-on-August-12-2021/ | VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. The live webcast of the earnings confere... | AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021 | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-06-10 17:11:00 | https://www.businesswire.com/news/home/20210610005969/en/AbCellera-Announces-Secondary-Private-Sale-of-11.9-Million-Common-Shares/ | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have e... | AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-31 08:44:17 | https://seekingalpha.com/article/4432222-abcellera-biologics-my-highest-conviction-pick-with-longest-potential-payoff | I recommended AbCellera on March 8, 2021, and so far the stock has gone pretty much nowhere. However, I am as bullish as ever. Immediate catalysts are lacking, but that does not preclude you from accumulating this stock at a reasonable valuation before the fireworks start. | AbCellera Biologics: My Highest Conviction Pick, With The Longest Potential Payoff | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-05-17 11:26:52 | https://pulse2.com/abcellera-nasdaq-abcl-stock-over-7-increase-explanation/ | The stock price of AbCellera (Nasdaq: ABCL) increased by over 7% during intraday trading this morning. This is why it happened. | AbCellera (ABCL) Stock: Over 7% Increase Explanation | ABCL | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.